New combo shot aims to reignite immune attack on tough melanoma

NCT ID NCT04796194

Completed Disease control Sponsor: Lytix Biopharma AS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of an injected drug (LTX-315) and an intravenous immunotherapy (pembrolizumab) in 23 people with advanced melanoma that no longer responded to standard PD-1/PD-L1 inhibitors. The goal was to see if the combination could shrink tumors or slow the disease. Participants had tumors that could be injected directly, such as those under the skin or in lymph nodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LTX-315 (injected into tumors) combined with pembrolizumab (IV infusion)
What this could lead to: If successful, this combination could offer a new treatment option for advanced melanoma patients whose cancer no longer responds to standard immunotherapy.
What could go wrong: This is a small, early-phase study with only 23 participants, so results may not apply broadly. The treatment involves injections into tumors and may cause side effects like pain, swelling, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA

Contacts and locations

Locations

Akershus University Hospital

Lørenskog, Norway
Centre Hospitalier Regional Universitaire De Lille

Lille, France
Clínica Universidad de Navarra

Pamplona, Spain
Gustave Roussy Cancer Campus

Paris, France
Hospital Lyon Sud

Pierre-Bénite, France
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Levine Cancer Institute - Atrium Health

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Centre

Houston, Texas, 77030, United States
Oslo University Hospital--Radiumhospitalet

Oslo, Norway
University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.